Kate Ward's presentation from Osteoporosis 2016: Relationships between muscle function and bone microarchitecture in the Hertfordshire cohort study.
Find out more at: https://nos.org.uk/conference
Prof. Jon Tobias's presentation from Osteoporosis 2016: Day-to-day levels of high impact physical activity are positively related to lower limb bone strength in older women: findings from a population based study using accelerometers to classify impact magnitude.
Find out more at: https://nos.org.uk/conference
Prof. Richard Keen's presentation from Osteoporosis 2016: Teaching old dogs new tricks? Combination therapy in osteoporosis.
Find out more at: https://nos.org.uk/conference
Prof. Jon Tobias's presentation from Osteoporosis 2016: Day-to-day levels of high impact physical activity are positively related to lower limb bone strength in older women: findings from a population based study using accelerometers to classify impact magnitude.
Find out more at: https://nos.org.uk/conference
Prof. Richard Keen's presentation from Osteoporosis 2016: Teaching old dogs new tricks? Combination therapy in osteoporosis.
Find out more at: https://nos.org.uk/conference
Prof. Richard Eastell's presentation from Osteoporosis 2016: Patients receiving bisphosphonates should take holidays from treatment. The case for holidays.
Find out more at: https://nos.org.uk/conference
Prof. Jon Tobias's presentation from Osteoporosis 2016: What are the properties of the perfect therapy?
Find out more at: https://nos.org.uk/conference
Tenslotte zal Prof. Dr. Joop van den Bergh het fractuurrisico bij patiënten met DM type 1 en 2 bespreken: hoe relevant is het verhoogde fractuurrisico bij jonge patiënten met DM type 1? Zijn adipeuze patiënten met DM type 2 beschermd tegen osteoporose? Welke determinanten spelen een rol bij het fractuurrisico bij DM type 2?
The Challenges of Sarcopenia: Definition, Underlying Mechanisms, Intervention...InsideScientific
During this webinar, Drs. Peterson and Guralnik will discuss sarcopenia, the physiological mechanisms underlying the disease, and the current avenues of treatment and assessment that are being researched and developed for patients.
Sarcopenia is the age-related loss of muscle that causes decreased strength and functional limitations. Muscle loss occurs universally in people as we age, but some people lose muscle at an accelerated rate compared to others. While chronic disease can cause sarcopenia, it can also result from a sedentary lifestyle, hospitalizations and extended bed rest due to other conditions.
A gradual decline in muscle mass and strength begins around 30 years of age with this condition, and annual losses get larger throughout life. The self-reporting of functional difficulties to health care providers may give an indication that sarcopenia is present, but a more precise definition is needed for research and clinical use.
Efforts made in Europe and the US have used grip strength, gait speed and lean mass to define sarcopenia, but these definitions lead to large differences in prevalence rate and discordance in who is labelled as “sarcopenic”. To assess this condition, lean mass as measured by dual x-ray absorptiometry (DXA) may not accurately reflect actual muscle mass, but a new technique using dilution of deuterium-labelled creatine may prove to be superior in clinically diagnosing sarcopenia. Currently, a consensus has not been reached on the clinical outcome assessments that can be used by regulatory agencies to judge the effectiveness of drugs for sarcopenia.
A number of potential interventions are being explored to treat sarcopenia in older people, but no drugs are currently approved for this condition. The antidiabetic drug metformin shows promise in preventing many age-associated conditions, but appears to blunt the benefits of exercise on muscle. Senolytic drugs, which clear senescent cells, may improve muscle repair following injury preferentially in older individuals.
Dr Steve Cummings presentation from Osteoporosis 2016: Patients receiving bisphosphonates should not take holidays from treatment.
Find out more at: https://nos.org.uk/conference
Structural Targets for Prevention of Post Traumatic OAOARSI
David Hunter MBBS, PhD, FRACP
Florance and Cope Chair of Rheumatology, Professor of Medicine
University of Sydney and Royal North Shore Hospital
Chair, Institute of Bone and Joint Research
Chair, Musculoskeletal, Sydney Medical Program
Consultant Rheumatologist, North Sydney Orthopedic and Sports Medicine
Definition of Osteoporosis - Prevalence - Risk factors for Osteoporosis - Diagnosis of Osteoporosis - Clinical manifestations- Laboratory investigations - DEXA - T and Z score - Management of Osteoporosis - Prevention
Prof. Richard Eastell's presentation from Osteoporosis 2016: Patients receiving bisphosphonates should take holidays from treatment. The case for holidays.
Find out more at: https://nos.org.uk/conference
Prof. Jon Tobias's presentation from Osteoporosis 2016: What are the properties of the perfect therapy?
Find out more at: https://nos.org.uk/conference
Tenslotte zal Prof. Dr. Joop van den Bergh het fractuurrisico bij patiënten met DM type 1 en 2 bespreken: hoe relevant is het verhoogde fractuurrisico bij jonge patiënten met DM type 1? Zijn adipeuze patiënten met DM type 2 beschermd tegen osteoporose? Welke determinanten spelen een rol bij het fractuurrisico bij DM type 2?
The Challenges of Sarcopenia: Definition, Underlying Mechanisms, Intervention...InsideScientific
During this webinar, Drs. Peterson and Guralnik will discuss sarcopenia, the physiological mechanisms underlying the disease, and the current avenues of treatment and assessment that are being researched and developed for patients.
Sarcopenia is the age-related loss of muscle that causes decreased strength and functional limitations. Muscle loss occurs universally in people as we age, but some people lose muscle at an accelerated rate compared to others. While chronic disease can cause sarcopenia, it can also result from a sedentary lifestyle, hospitalizations and extended bed rest due to other conditions.
A gradual decline in muscle mass and strength begins around 30 years of age with this condition, and annual losses get larger throughout life. The self-reporting of functional difficulties to health care providers may give an indication that sarcopenia is present, but a more precise definition is needed for research and clinical use.
Efforts made in Europe and the US have used grip strength, gait speed and lean mass to define sarcopenia, but these definitions lead to large differences in prevalence rate and discordance in who is labelled as “sarcopenic”. To assess this condition, lean mass as measured by dual x-ray absorptiometry (DXA) may not accurately reflect actual muscle mass, but a new technique using dilution of deuterium-labelled creatine may prove to be superior in clinically diagnosing sarcopenia. Currently, a consensus has not been reached on the clinical outcome assessments that can be used by regulatory agencies to judge the effectiveness of drugs for sarcopenia.
A number of potential interventions are being explored to treat sarcopenia in older people, but no drugs are currently approved for this condition. The antidiabetic drug metformin shows promise in preventing many age-associated conditions, but appears to blunt the benefits of exercise on muscle. Senolytic drugs, which clear senescent cells, may improve muscle repair following injury preferentially in older individuals.
Dr Steve Cummings presentation from Osteoporosis 2016: Patients receiving bisphosphonates should not take holidays from treatment.
Find out more at: https://nos.org.uk/conference
Structural Targets for Prevention of Post Traumatic OAOARSI
David Hunter MBBS, PhD, FRACP
Florance and Cope Chair of Rheumatology, Professor of Medicine
University of Sydney and Royal North Shore Hospital
Chair, Institute of Bone and Joint Research
Chair, Musculoskeletal, Sydney Medical Program
Consultant Rheumatologist, North Sydney Orthopedic and Sports Medicine
Definition of Osteoporosis - Prevalence - Risk factors for Osteoporosis - Diagnosis of Osteoporosis - Clinical manifestations- Laboratory investigations - DEXA - T and Z score - Management of Osteoporosis - Prevention
Frank de Vries's presentation from Osteoporosis 2016: The epidemiology of mortality after fragility fracture in England and Wales.
Find out more at: https://nos.org.uk/conference
Arti Gauvri Bhimjiyani's presentation from Osteoporosis 2016: The effect of social deprivation on hip fracture incidence has not changed over 10 years in England.
Find out more at: https://nos.org.uk/conference
Arti Gauvri Bhimjiyani's presentation from Osteoporosis 2016: The effect of social deprivation on hip fracture incidence has not changed over 10 years in England.
Find out more at: https://nos.org.uk/conference
Bo Abrahamsen's presentation from Osteoporosis 2016: Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment.
Find out more at: https://nos.org.uk/conference
Elizabeth Curtis's presentation from Osteoporosis 2016: Variation in UK fracture incidence by age, sex, geography, ethnicity, socioeconomic status, and time: results from the UK CPRD:
Find out more at: https://nos.org.uk/conference
Prof. Nicholas Harvey's presentation from Osteoporosis 2016: Calcium, with or without vitamin D supplementation, is not associated with ischaemic heart disease or cardiac death: the UK Biobank cohort.
Find out more at: https://nos.org.uk/conference
Frank de Vries's presentation from Osteoporosis 2016: The epidemiology of mortality after fragility fracture in England and Wales.
Find out more at: https://nos.org.uk/conference
Prof. Eugene McCloskey's presentation from Osteoporosis 2016: Assessment and intervention thresholds for FRAX probabilities in the UK- Impact on the need for BMD in older women with prior fracture
Find out more at: https://nos.org.uk/conference
Dr Andrea Burden's presentation from Osteoporosis 2016: Intermittent use of high-dose glucocorticoids and risk of fracture in Denmark: A population-based case-control study.
Find out more at: https://nos.org.uk/conference
Dr Jennifer Walsh's presentation from Osteoporosis 2016: Management of osteoporosis in the young adult.
Find out more at: https://nos.org.uk/conference
Dr Rachel Tattersall's presentation from Osteoporosis 2016: Successful transition from paediatric to adult services.
Find out more at: https://nos.org.uk/conference
Osteoporosis 2016 | Successful transition from paediatric to adult services: ...
Similar to Osteoporosis 2016 | Relationships between muscle function and bone microarchitecture in the Hertfordshire cohort study: Kate Ward #osteo2016
Integrating TBS Into Your Clinical Practice.pdfssuser4eaa71
Today’s current technology for diagnosing osteoporosis only measures bone density, which is only half of the World Health Organization's definition of osteoporosis. The full definition includes bone mineral density (BMD) and microarchitecture - trabecular bone score (TBS).
Similar to Osteoporosis 2016 | Relationships between muscle function and bone microarchitecture in the Hertfordshire cohort study: Kate Ward #osteo2016 (20)
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
Osteoporosis 2016 | Relationships between muscle function and bone microarchitecture in the Hertfordshire cohort study: Kate Ward #osteo2016
1. Relationships between muscle function
and bone microarchitecture in the
Hertfordshire Cohort Study
KA Ward, MH Edwards, K Jameson, S Shaw, H Syddall, C
Cooper, EM Dennison
MRC Lifecourse Epidemiology Unit, University of Southampton
MRC Elsie Widdowson Laboratory, Cambridge
2. Musculoskeletal ageing
• By 2050 2 milliards of people aged
>65 years, c.f. 600 million today
• Osteoporosis: 1 in 2 women, 1 in 5
men > 50 yrs.
• Sarcopenia: No defined consensus,
IWGS, EWGSOP, FNIH.
• Healthcare costs:
• OP - £2million/day, £5 billion/yr
• Sarcopenia - >$18 billion in the US
2001
• Sarcopenia, falls and fracture
prevention
Hertfordshire Cohort Study
• Lean mass indices – cortical area
and thickness
• Fat mass indices – trabecular
density, number independent of LMI
• Compartmental effects cortical vs
trabecular bone, lean mass vs. fat
• Muscle strength – mass, anatomy
(fibre composition, IMAT, pennation
angle), force and power generating
capacity
Edwards MH, PhD Thesis 2014
Edwards 2015, Bone, 81 145-151
4. Power – functional capacity, e.g arresting a fall, walk speed
Force – measure of the load to bone
Efficiency – how well you utilise force to generate power
5. Methods
• 184 (144) men and 166 (104) women,
mean (SD) age M 75.9 (2.4), F 75.9
(2.6)
• HRpQCT of the tibia and radius (X-
Treme I™, Scanco Medical)
• 2-leg countermovement jump to
assess jump force and power
(Leonardo ™, Novotec Medical)
• Linear regression models, males and
females separately
• age, weight, height
• social class, smoking status,
calcium intake, hormone
replacement use and years since
menopause in women.
10. Conclusions
• In women, greater muscle power and force had more
cortical and trabecular bone
• In men, consistent negative associations with porosity
were found, suggesting lower turnover with greater
power
• No associations between pQCT and jump parameters
(data not shown) at the distal or diaphyseal sites
• LMI and FMI are more consistent predictors of bone
microarchitecture in older adults (function vs. mass).
• Findings are less strong and more inconsistent than in
other cohorts who are in general younger and have a
wider range of ages.
11. Acknowledgements
Co-authors
Mark Edwards, Cyrus Cooper, Elaine Dennison
Karen Jameson, Sarah Shaw, Holly Sydall
Funding
Medical Research Council
Study Participants
Hertfordshire Cohort Study
12. Lean mass indices: men
Unadjusted Fully adjusted
N
Regression
coefficient
95% CI p-value N
Regression
coefficient
95% CI p-value
tibia total area
135 -0.035 (-0.207, 0.136) 0.684 122 -0.041 (-0.230, 0.148) 0.667
tibia cortical
area 136 0.499 (0.349, 0.648) <0.001 123 0.524 (0.358, 0.691) <0.001
tibia trabecular
area 137 -0.125 (-0.296, 0.046) 0.152 123 -0.137 (-0.322, 0.048) 0.146
tibia apparent
cortical
thickness 136 0.437 (0.282, 0.593) <0.001 123 0.462 (0.295, 0.628) <0.001
tibia cortical
BMD 136 0.148 (-0.022, 0.318) 0.087 123 0.105 (-0.077, 0.287) 0.255
tibia cortical
porosity 136 0.023 (-0.141, 0.187) 0.783 123 0.082 (-0.097, 0.261) 0.365
tibia trabecular
density 137 0.132 (-0.035, 0.299) 0.119 123 0.172 (-0.010, 0.354) 0.064
tibia trabecular
number 137 0.262 (0.110, 0.415) 0.001 123 0.259 (0.088, 0.430) 0.003
tibia trabecular
thickness 137 -0.065 (-0.235, 0.106) 0.453 123 -0.008 (-0.191, 0.174) 0.927
Results are an SD change per one SD change in predictor
Adjusted for age, height, weight, social class, smoker status, alcohol consumption, activity, dietary calcium and HRT use and years since
menopause in women
13. Lean mass indices: women
Unadjusted Fully adjusted
N
Regression
coefficient
95% CI p-value N
Regression
coefficient
95% CI p-value
tibia total area
100 0.134 (-0.065, 0.333) 0.184 91 0.087 (-0.143, 0.317) 0.454
tibia cortical
area 100 0.489 (0.313, 0.664) <0.001 91 0.498 (0.293, 0.704) <0.001
tibia trabecular
area 100 0.060 (-0.140, 0.261) 0.553 91 0.012 (-0.222, 0.245) 0.921
tibia apparent
cortical
thickness 100 0.314 (0.123, 0.505) 0.002 91 0.339 (0.115, 0.563) 0.004
tibia cortical
BMD 100 0.248 (0.051, 0.445) 0.014 91 0.271 (0.046, 0.496) 0.019
tibia cortical
porosity 100 -0.132 (-0.333, 0.070) 0.197 91 -0.143 (-0.375, 0.088) 0.221
tibia trabecular
density 100 0.007 (-0.194, 0.208) 0.946 91 0.051 (-0.186, 0.289) 0.668
tibia trabecular
number 100 0.138 (-0.063, 0.339) 0.175 91 0.155 (-0.071, 0.381) 0.177
tibia trabecular
thickness 100 -0.073 (-0.272, 0.126) 0.469 91 -0.025 (-0.259, 0.210) 0.835
Results are an SD change per one SD change in predictor
Adjusted for age, height, weight, social class, smoker status, alcohol consumption, activity, dietary calcium and HRT use and years since
menopause in women
Editor's Notes
I’d like to finish by thanking my coauthors, my funders, and the participants of the Hertfordshire Cohort Study. Thank you.